Key result
Roux-en-Y gastric bypass reduces NASH prevalence by ~84% at 16 months post-surgery.
Why the study?
The effects of surgical weight loss by Roux-en-Y gastric bypass on non alcoholic fatty liver disease in morbidly obese patients were evaluated.
Does Roux-en-Y gastric bypass improve non-alcoholic fatty liver disease in morbidly obese patients?
Cohort (n=26)
Blinded (for biopsy evaluation)
Does Roux-en-Y gastric bypass improve non-alcoholic fatty liver disease in morbidly obese patients?
Answers are grounded in this paper and cite their sources.
Surgically induced weight loss via Roux-en-Y gastric bypass significantly improves liver histology and resolves metabolic syndrome in morbidly obese patients with non-alcoholic fatty liver disease.
AIM: To evaluate the effects of surgical weight loss (Roux-en-Y gastric bypass with a modified Fobi-Capella technique) on non alcoholic fatty liver disease in obese patients. METHODS: A group of 26 morbidly obese patients aged 45 ± 2 years and with a body mass index > 40 kg/m(2) who underwent open surgical weight loss operations had paired liver biopsies, the first at surgery and the second after 16 ± 3 mo of weight loss. Biopsies were evaluated and compared in a blinded fashion. The presence of metabolic syndrome, anthropometric and biochemical variables were also assessed at baseline and at the time of the second biopsy. RESULTS: Percentage of excess weight loss was 72.1% ± 6.6%. There was a reduction in prevalence of metabolic syndrome from 57.7% (15 patients) to 7.7% (2 patients) (P < 0.001). Any significance difference was observed in aspartate aminotransferase or alanine aminotransferase between pre and postsurgery. There were improvements in steatosis (P < 0.001), lobular (P < 0.001) and portal (P < 0.05) inflammation and fibrosis (P < 0.001) at the second biopsy. There were 25 (96.1%) patients with non alcoholic steatohepatitis (NASH) in their index biopsy and only four (15.3%) of the repeat biopsies fulfilled the criteria for NASH. The persistence of fibrosis (F > 1) was present in five patients at second biopsy. Steatosis and fibrosis at surgery were predictors of significant fibrosis postsurgery. CONCLUSION: Restrictive mildly malabsorptive surgery provides significant weight loss, resolution of metabolic syndrome and associated abnormal liver histological features in most obese patients.
No takes yet. Share an insight, caveat, or question.
Vargas et al. (2012) conducted a cohort in Non-alcoholic fatty liver disease in morbid obesity (n=26). Roux-en-Y gastric bypass vs. Baseline (pre-surgery) was evaluated on Non-alcoholic steatohepatitis (NASH) prevalence. Roux-en-Y gastric bypass reduced the prevalence of non-alcoholic steatohepatitis from 96.1% at baseline to 15.3% at 16 months post-surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: